Genomes and Genes
Summary: Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.
Publications147 found, 100 shown here
- [Cholera vaccine]Masahiko Ehara
Department of Bacteriology, Institute of Tropical Medicine, Nagasaki University
Nippon Rinsho 63:625-30. 2005
- Process development for a Cuban cholera vaccine based on the attenuated strain Vibrio cholerae 638A Talavera
Finlay Institute, 27 Ave, 19805 La Lisa, Ciudad de La Habana, A P 16017, Cod 11600, Cuba
Vaccine 24:3746-9. 2006..We conclude that the non-reactogenic, immunogenic and protective strain 638 is robust and can withstand the fermentation processes required for large-scale production of a vaccine...
- CholeraDavid A Sack
International Centre for Diarrhoeal Disease Research, Bangladesh, Centre for Health and Population Research, Dhaka, Bangladesh
Lancet 363:223-33. 2004..Appropriate case management has reduced deaths from diarrhoeal disease by an estimated 3 million per year compared with 20 years ago. Vaccination was thought to have no role for cholera, but new oral vaccines are showing great promise...
- Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trialDipika Sur
National Institute of Cholera and Enteric Diseases, Kolkata, India
Lancet 374:1694-702. 2009Oral cholera vaccines consisting of killed whole cells have been available for many years, but they have not been used extensively in populations with endemic disease...
- Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trialSuman Kanungo
National Institute of Cholera and Enteric Diseases, Kolkata, India
Vaccine 27:6887-93. 2009..Responses to V. cholerae O139 were less pronounced but followed a similar pattern. We demonstrate that in a cholera-endemic area, the vaccine elicited vibriocidal responses after a single-dose of the vaccine...
- Efficacy calculation in randomized trials: global or local measures?Michael Emch
Department of Geography, Saunders Hall, University of North Carolina, Chapel Hill, NC 27599 3220 USA
Health Place 13:238-48. 2007..Local efficacy measures can help public health practitioners make better decisions about when and where to vaccinate populations. The concepts offered in this study are pertinent for any health intervention trial, not just vaccines...
- Novel type of specialized transduction for CTX phi or its satellite phage RS1 mediated by filamentous phage VGJ phi in Vibrio choleraeJavier Campos
Departamento de Genetica, Centro Nacional de Investigaciones Cientificas, AP 6412, Havana, Cuba
J Bacteriol 185:7231-40. 2003..cholerae and the importance of our findings for the development of an environmentally safer live attenuated cholera vaccine...
- Human infection with Ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin B subunit following vaccination with the live oral cholera vaccine CVD 103-HgRP J Cooper
Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Infect Immun 69:1574-80. 2001..The potential modulation of the immune response to oral vaccines by geohelminth parasites has important implications for the design of vaccination campaigns in geohelminth-endemic areas...
- Controlling endemic cholera with oral vaccinesIra M Longini
Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
PLoS Med 4:e336. 2007..Internationally licensed, killed whole-cell based oral cholera vaccines (OCVs) have been available for over a decade, but have not been used for the control of cholera...
- Oral cholera vaccines: use in clinical practiceDavid R Hill
National Travel Health Network and Centre, London, UK
Lancet Infect Dis 6:361-73. 2006Cholera continues to occur globally, particularly in sub-Saharan Africa and Asia. Oral cholera vaccines have been developed and have now been used for several years, primarily in traveller populations...
- A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, IndiaDilip Mahalanabis
Society for Applied Studies, Kolkata, India
PLoS ONE 3:e2323. 2008..This vaccine was reformulated to meet WHO requirements. We assessed the safety and immunogenicity of the reformulated bivalent (Vibrio cholerae 01 and 0139) killed whole cell oral vaccine in a cholera endemic area in Kolkata, India...
- Use of oral cholera vaccines in an outbreak in Vietnam: a case control studyDang Duc Anh
National Institute of Hygiene and Epidemiology NIHE, Hanoi, Vietnam
PLoS Negl Trop Dis 5:e1006. 2011Killed oral cholera vaccines (OCVs) are available but not used routinely for cholera control except in Vietnam, which produces its own vaccine...
- What about cholera vaccines?Claire Lise Chaignat
Expert Rev Vaccines 7:403-5. 2008
- Cholera in disasters: do vaccines prompt new hopes?Claire Lise Chaignat
Global Task Force on Cholera Control, Department of Neglected Tropical Diseases, Communicable Diseases Cluster, World Health Organization, 20, Av Appia, 1211 Geneva 27, Switzerland
Expert Rev Vaccines 7:431-5. 2008..Fears of cholera outbreaks are often rife in such conditions and the pertinence of using cholera vaccines, now available on the market, merit attention...
- Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccinesJean François Faucher
Medical Research Unit, Albert Schweitzer Hospital, Lambarene, Gabon
Clin Infect Dis 35:1147-54. 2002..The A-P combination was highly effective for malaria prophylaxis, without interfering with the in vivo immunogenicity of CVD103-HgR and Ty21a vaccines, and it could therefore be simultaneously administered with these vaccines...
- Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysisMarc Jeuland
Department of Environmental Sciences and Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Value Health 12:899-908. 2009..Our analysis incorporated new findings on vaccine herd protective effects...
- Private demand for cholera vaccines in Hue, VietnamDohyeong Kim
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Value Health 11:119-28. 2008This study aims to measure the private demand for oral cholera vaccines in Hue, Vietnam, an area of relatively low endemicity of cholera, using the contingent valuation method.
- Relationship between neighbourhood-level killed oral cholera vaccine coverage and protective efficacy: evidence for herd immunityMichael Emch
Department of Geography, Saunders Hall, Campus Box 3220, University of North Carolina Chapel Hill, 27599 3220, USA
Int J Epidemiol 35:1044-50. 2006....
- Cholera: the need to translate research knowledge into effective preventive and control measuresG Balakrish Nair
Future Microbiol 3:379-81. 2008
- Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgRP J Cooper
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0425, USA
J Infect Dis 182:1199-206. 2000..lumbricoides infections impair the immune response to oral cholera vaccine, particularly in subjects of non-O blood groups...
- Can oral cholera vaccination play a role in controlling a cholera outbreak?Philippe Calain
WHO Western Pacific Regional Office, Manila, Philippines
Vaccine 22:2444-51. 2004..9-84.6%) in the target population. Retrospective analysis suggests that mass vaccination with oral cholera vaccines can be a useful adjunct tool for controlling outbreaks, particularly if implemented early in association with ..
- Coverage and costs of mass immunization of an oral cholera vaccine in VietnamDinh Thiem Vu
National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
J Health Popul Nutr 21:304-8. 2003..89. Mass immunization with this locally-produced oral, killed cholera vaccine was found to be feasible and affordable with attainment of high vaccination coverage...
- Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan childrenH O Hallander
Swedish Institute for Infectious Disease Control, Solna, Sweden
Vaccine 21:138-45. 2002Serum responses to oral cholera vaccines were assessed in three paediatric vaccine trials, two in LeÃ³n, Nicaragua and one in Stockholm, Sweden...
- Sample size determination for phase II studies of new vaccinesMalla R Rao
National Institute of Child Health and Human Development, Bethesda, MD 20892, USA
Vaccine 20:3364-9. 2002..We also consider a setting in which the desire is to show that the difference between immune response rates for vaccine and control is greater than a specified value...
- The value of cholera vaccines reassessedRoger I Glass
Viral Gastroenteritis Section, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Lancet 366:7-9. 2005
- Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infantsFirdausi Qadri
ICDDR, B Centre for Health and Population Research, Bangladesh
Vaccine 25:231-8. 2007..The responses to the reduced dose was lower. These studies demonstrate that Peru-15 at a dose of 2x10(8)cfu is safe and immunogenic in children in Bangladesh...
- The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteersLuis Garcia
Centro Nacional de Investigaciones Cientificas, P O Box 6412, Avenida 25, Esquina a 158, Ciudad de La Habana, Cuba
Infect Immun 73:3018-24. 2005..cholerae 3008. We recommend that additional vaccine lots of 638 be prepared under good manufacturing practices for further evaluation...
- Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in BangladeshFirdausi Qadri
International Centre for Diarrhoeal Disease Research, Bangladesh ICDDR, B Centre for Health and Population Research, Dhaka, Bangladesh
J Infect Dis 192:573-9. 2005..A lower immunological response against cholera toxin B subunit was detected.CONCLUSIONS. The safety and immunogenicity of this Peru-15 vaccine candidate indicates the usefulness of future studies in Bangladesh, where cholera is endemic...
- Suppressive effect of zinc on antibody response to cholera toxin in children given the killed, B subunit-whole cell, oral cholera vaccineFirdausi Qadri
International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh
Vaccine 22:416-21. 2004..Thus, zinc enhanced vibriocidal antibody response, but suppressed CT-antibody response, suggesting that zinc supplementation has different modulating effects on vibriocidal antibody response and CT-antibody response...
- Effectiveness of mass oral cholera vaccination in Beira, MozambiqueMarcelino E S Lucas
Ministry of Health, Maputo, Mozambique
N Engl J Med 352:757-67. 2005BACKGROUND: New-generation, orally administered cholera vaccines offer the promise of improved control of cholera in sub-Saharan Africa...
- Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysisMohammad Ali
International Vaccine Institute, Seoul, Korea
Lancet 366:44-9. 2005BACKGROUND: Decisions about the use of killed oral cholera vaccines, which confer moderate levels of direct protection to vaccinees, can depend on whether the vaccines also provide indirect (herd) protection when high levels of vaccine ..
- Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in VietnamVu Dinh Thiem
National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
Vaccine 24:4297-303. 2006..The overall vaccine effectiveness 3-5 years after vaccination was 50% (9-63%). This low-cost, easily administered vaccine should be considered as a tool for the control of cholera...
- When should cholera vaccine be used in cholera-endemic areas?David A Sack
J Health Popul Nutr 21:299-303. 2003
- Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in BangladeshFirdausi Qadri
International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka
Infect Immun 73:6577-83. 2005..cholerae O139. Consequently, this assay may be useful in studies of both O139-infected patients and recipients of O139 vaccines...
- Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgRJean Francois Viret
Berna Biotech Ltd, Rehhagstrasse 79, CH 3018 Berne, Switzerland
Vaccine 22:2457-69. 2004..In this contribution we address selected aspects of the risk assessment of live attenuated bacterial vaccines covered in the course of the registration of vaccine strain CVD 103-HgR as a recombinant live oral vaccine against cholera...
- [Examples for vaccines against diarrheal diseases--rotavirus and traveller's diarrhea]Herwig Kollaritsch
Institut für Spezifische Prophylaxe und Tropenmedizin, Zentrum für Physiologie und Pathophysiologie, Medizinische Universität Wien, Kinderspitalgasse 15, Vienna, Austria
Wien Med Wochenschr 157:102-6. 2007..Both vaccines display 85-98% efficacy against severe rotavirus disease and an excellent tolerability with no difference in side reactions to the placebo controls, particularly with respect to intussusceptions...
- Cholera: a new homeland in Africa?Nicholas H Gaffga
Division of Foodborne, Mycotic, and Enteric Diseases, National Center for Zoonotic, Vectorborne, and Enteric Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Am J Trop Med Hyg 77:705-13. 2007..The persistence or control of cholera in Africa will be a key indicator of global efforts to reach the Millennium Development Goals and of recent commitments by leaders of the G-8 countries to increase development aid to the region...
- Vaccines on trialParoma Basu
Nature 436:484. 2005
- Sensitive microplate assay for detection of bactericidal antibodies to Vibrio cholerae O139Stephen R Attridge
Department of Molecular Biosciences, University of Adelaide, Adelaide, South Australia 5005, Australia
Clin Diagn Lab Immunol 9:383-7. 2002..Although infection generated stronger responses than vaccination, the proportion of responders was similar among individuals with low background titers...
- CTXphi immunity: application in the development of cholera vaccinesH H Kimsey
Division of Geographic Medicine and Infectious Diseases, Tupper Research Institute, Tufts New England Medical Center 041, 750 Washington Street, Boston, MA 02111, USA
Proc Natl Acad Sci U S A 95:7035-9. 1998..cholerae vaccine strains effectively protected these vaccines from CTXphi infection. Introduction of rstR into V. cholerae vaccine strains should enhance their biosafety...
- Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in miceJ Y Wu
Department of Microbiology and Immunology, Dartmouth Medical School, Hanover, New Hampshire 03755, USA
Infect Immun 69:7695-702. 2001..These results indicate that specific regions of TcpA, including those delineated by the peptides used in this study, have the potential to be incorporated into an effective defined subunit vaccine for cholera...
- Cholera vaccines for the developing worldAnna Lena Lopez
International Vaccine Institute, Seoul, Korea
Hum Vaccin 4:165-9. 2008..Since 1999, the World Health Organization has advocated the use of oral cholera vaccines as an adjunct in the control of cholera...
- Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccinationC O Tacket
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
Infect Immun 67:6341-5. 1999..Peak stool V. cholerae excretion among placebo recipients was 1.1 x 10(7) CFU/g and among vaccinees was 4.9 x 10(2) CFU/g (P < 0.001). This vaccine could therefore be a safe and effective tool to prevent cholera in travelers...
- Use of oral cholera vaccine in complex emergencies: what next? Summary report of an expert meeting and recommendations of WHOClaire Lise Chaignat
Global Task Force on Cholera Control, World Health Organization, Avenue Appia 20, CH 1211 Geneva 27, Switzerland
J Health Popul Nutr 25:244-61. 2007Two meetings of the World Health Organization (WHO)-in 1999 and 2002-had examined the potential use of oral cholera vaccines (OCVs) as an additional public-health tool for the control of cholera...
- Mass vaccination with a two-dose oral cholera vaccine in a refugee campD Legros
Epicentre, Kampala, Uganda
Bull World Health Organ 77:837-42. 1999In refugee settings, the use of cholera vaccines is controversial since a mass vaccination campaign might disrupt other priority interventions...
- Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet NamD D Trach
National Institute of Hygiene and Epidemiology, Hanoi, Viet Nam
Bull World Health Organ 80:2-8. 2002..CONCLUSION: It was concluded that biv-WC was safe and immunogenic, that it could be administered without buffer, and that it could elicit robust immune responses even in children, for whom the risk of endemic cholera is highest...
- A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in MaliR T Perry
Department of Pediatrics, University of Maryland School of Medicine, Baltimore, USA
Bull World Health Organ 76:63-71. 1998..These results encourage further evaluations of this single-dose, oral cholera vaccine in high-risk populations such as refugees in sub-Saharan Africa...
- Cholera vaccinesE T Ryan
Tropical and Geographic Medicine Center, Travelers Advice and Immunization Center, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA
Clin Infect Dis 31:561-5. 2000..cholerae for at least 6 months. No commercially available cholera vaccine protects against disease caused by V. cholerae serogroup O139. New cholera vaccines are being developed.
- Getting serious about choleraDavid A Sack
International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh
N Engl J Med 355:649-51. 2006
- The true burden and risk of cholera: implications for prevention and controlJane N Zuckerman
Academic Centre for Travel Medicine and Vaccines, WHO Collaborating Centre for Travel Medicine, Royal Free and University College Medical School, London, UK
Lancet Infect Dis 7:521-30. 2007..However, a vaccine against cholera is now available that has proven efficacy and tolerability in mass vaccination campaigns in low-income countries, and among travellers...
- Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrheaJonas Lundkvist
i3innovus, Stockholm, Sweden
J Travel Med 16:28-34. 2009....
- Effectiveness in prevention of travellers' diarrhoea by an oral cholera vaccine WC/rBSR Lopez-Gigosos
International Vaccination Centre, Offices of the Health Area, Sub Delegation of the Government of Malaga, Paseo Marítimo de Pablo Ruiz Picasso 43, Malaga 29070, Spain
Travel Med Infect Dis 5:380-4. 2007..To investigate the effectiveness of an oral cholera vaccine (Dukoral((R))) in preventing travellers' diarrhoea...
- Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrheaRobert Steffen
Institute for Social and Preventive Medicine (ISPM, World Health Organization (WHO) Collaborating Center for Travelers' Health, University of Zurich, Switzerland
J Travel Med 12:102-7. 2005
- Private demand for cholera vaccines in rural Matlab, BangladeshZiaul Islam
Health Systems and Infectious Diseases Division, International Centre for Diarrhoeal Disease Research ICDDR, B, Dhaka, Bangladesh
Health Policy 85:184-95. 2008To estimate household willingness to pay (WTP) for cholera vaccines in a rural area of Bangladesh, which had participated in a 1985 oral cholera vaccine trial.
- Private demand for cholera vaccines in Beira, MozambiqueMarcelino E S Lucas
Ministry of Science and Technology, Maputo, Mozambique
Vaccine 25:2599-609. 2007..We estimate average household willingness to pay (WTP) for cholera vaccines in Beira to be 2005 US$ 8.45...
- Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adultsDang Duc Anh
National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
Vaccine 25:1149-55. 2007..We found that this reformulated oral killed whole-cell cholera vaccine was safe, well tolerated and highly immunogenic...
- Role of toll-like receptor 4 in the proinflammatory response to Vibrio cholerae O1 El tor strains deficient in production of cholera toxin and accessory toxinsG Kenneth Haines
Northwestern University, Dept of Microbiology Immunology, 303 E Chicago Avenue, Tarry 3 713, Chicago, IL 60611, USA
Infect Immun 73:6157-64. 2005..Morbidity is enhanced in C3H/HeJ mice, indicating that Toll-like receptor 4 is important for infection containment...
- Oral immunogenicity of the inactivated Vibrio cholerae whole-cell vaccine encapsulated in biodegradable microparticlesMing Kung Yeh
Department of Clinical Pharmacy and Clinical Pharmacy Research Laboratory, Room 6345, Tri Service General Hospital, National Defence Medical Center, 325 Sec 2 Chen kung R D, Neihu, 114, Taipei, Taiwan
J Control Release 82:237-47. 2002..The VC incorporation, physicochemical characterization data, and the animal results obtained in this study may be relevant in optimizing the vaccine incorporation and delivery properties of these potential vaccine targeting carriers...
- Formulation in tablets of a cholera whole cells inactivated vaccine candidateA Talavera
Finlay Institut, 27 Ave 19805, La Lisa, Ciudad de La Habana, A P 16017, Cod 11600, Cuba
Vaccine 24:3381-7. 2006Licensed as well as candidate cholera vaccines available at the present requires the dose preparation (included buffer) at the moment of application...
- Cholera vaccinesShahjahan Kabir
Lancet Infect Dis 7:176-8; author reply 178. 2007
- [Cholera: recent acquisitions]Salvatore Nardiello
Dipartimento Assistenziale di Malattie Infettive, Seconda Universita degli Studi di Napoli
Infez Med 15:85-92. 2007..We have reviewed the most recent hypothesis on the ecology of cholera, in particular on the origin of epidemics. Recent developments in the fields of therapy and prophylaxis of cholera are also reported...
- Progress towards development of a cholera subunit vaccineRonald K Taylor
Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, NH 03756, USA
Chem Biodivers 1:1036-57. 2004..cholerae exposed or vaccinated individuals. This review discusses the current cholera vaccines and compares the advantages of a cholera subunit vaccine to that of the whole cell vaccines...
- The ABCs (Antibody, B cells, and Carbohydrate epitopes) of cholera immunity: considerations for an improved vaccineDaniele Provenzano
Department of Biological Sciences, University of Texas-Brownsville, Brownsville, TX 78520, USA
Microbiol Immunol 50:899-927. 2006....
- Questionable merits of the field trial of an oral killed whole cell cholera vaccine in Vietnam during 1998-2003Shahjahan Kabir
Vaccine 25:1353-4. 2007
- A semi-automated vibriocidal assay for improved measurement of cholera vaccine-induced immune responsesJae Seung Yang
Laboratory Sciences Division, International Vaccine Institute, Seoul 151 600, Republic of Korea
J Microbiol Methods 71:141-6. 2007....
- Response to "questionable merits of the field trial of an oral killed whole cell cholera vaccine in Vietnam during 1998-2003" Vaccine 2007;25(8):1353-4Vu Dinh Thiem
Vaccine 25:7981-3. 2007
- [Selection of attenuated Vibrio cholerae strains to obtain oral attenuated candidate vaccines against cholera]Hilda María García
Instituto Finlay, Ciudad de La Habana, Cuba
Rev Cubana Med Trop 57:92-104. 2005..All the strains were sensitive to tetracycline and doxoclycine. They showed their attenuation and immunogenicity in animal models. The strains 638 and 1333 proved to be immunogenic and non reactogenic in volunteers...
- A recombinant probiotic for treatment and prevention of choleraAntonio Focareta
School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia
Gastroenterology 130:1688-95. 2006..In the present study, this has been applied to the development of a recombinant probiotic for treatment and prevention of cholera, caused by Vibrio cholerae...
- A Vibrio cholerae serogroup O1 vaccine candidate against CTX ET Phi infectionMeiying Yan
State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, PR China
Vaccine 25:4046-55. 2007..Thus, IEM109 is a stable vaccine candidate that evokes not only antitoxic and vibriocidal immunities, but also resistance to the El Tor biotype CTX Phi infection...
- Exploiting cholera vaccines as a versatile antigen delivery platformAnisia J Silva
Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Dr, SW Atlanta, GA 30310, USA
Biotechnol Lett 30:571-9. 2008..Foreign antigens can be delivered to the immune system with cholera vaccines by expressing heterologous antigens in live attenuated vectors, as fusion proteins with cholera toxin ..
- Construction and evaluation of a O139 Vibrio cholerae vaccine candidate based on a hemA gene mutationManickam Ravichandran
Department of Medical Microbiology and Parasitology, School of Medical Sciences, Universiti Sains Malaysia Health Campus, Kubang Kerian 16150, Kelantan, Malaysia
Vaccine 24:3750-61. 2006..VCUSM2 is thus a potential vaccine candidate against infection by V. cholerae O139...
- Inactive Vibrio cholerae whole-cell vaccine-loaded biodegradable microparticles: in vitro release and oral vaccinationM K Yeh
Department of Clinical Pharmacy, and Pediatric Tri service General Hospital, National Defense Medical Center 325, Sec 2 Chen kung R D Neihu Taipei 114 Taiwan
J Microencapsul 21:91-106. 2004..The most immunogenicity in evoking serum IgG, IgA and IgM responses was immunized by VC-loaded PLA/PEG-blended microparticles, and with VC challenge in mice, the survival rate (91.7%)...
- Infection and immunity to Vibrio cholerae, Salmonella typhimurium and Escherichia coli in a rabbit modelP A Guinee
National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands
Zentralbl Bakteriol Mikrobiol Hyg A 270:260-9. 1988..Therefore, further attenuation of non-toxigenic V. cholerae strains by means of stable deletions in nutritional genes seems to be the most promising way to obtain acceptable vaccine candidates...
- Protective immunity against Vibrio cholerae infection in the rabbitP A Guinee
National Institute of Public Health and Environmental Hygiene, Bilthoven, The Netherlands
Zentralbl Bakteriol Mikrobiol Hyg A 266:552-62. 1987..The results obtained on the rabbit model are discussed in relation to the efficacy of this vaccine in human volunteers and in a recent field test...
- CholeraP Shears
Centre for Tropical Medical Microbiology, Liverpool School of Tropical Medicine
Ann Trop Med Parasitol 88:109-22. 1994..Developments in the molecular characterization of V. cholerae are providing new information to explain the genetic and epidemiological variations...
- Construction and characterisation of O139 cholera vaccine candidatesTalena Ledón
Grupo de Genética, Centro Nacional de Investigaciones Cientificas, AP 6412 Havana, Cuba
Vaccine 21:1282-91. 2003..All the strains here obtained showed similar phenotypes in traits known to be remarkable for live cholera vaccines irrespective of their motility phenotypes, although the hapA mutants had a 10-fold decrease in their ..
- Experience with registered mucosal vaccinesGuido Dietrich
Berna Biotech Ltd, Rehhagstr 79, CH-3018, Berne, Switzerland
Vaccine 21:678-83. 2003..typhi Ty21a as well as V. cholerae CVD 103-HgR-are employed as vaccines against typhoid and cholera, respectively. In this manuscript, we review the immune responses that are induced by these vaccines, with a focus on mucosal immunity...
- Vibrio cholerae and cholera: out of the water and into the hostJoachim Reidl
Zentrum für Infektionsforschung, Universitat Wurzburg, Wurzburg, Germany
FEMS Microbiol Rev 26:125-39. 2002..More recently, researchers have been elucidating the environmental lifestyle of V. cholerae. This review provides an overview of the current knowledge of both the host- and environment-specific physiological attributes of V. cholerae...
- Home-grown Vietnamese cholera vaccine "completely safe"Mary Quirk
Lancet Infect Dis 2:198. 2002
- DNA adenine methylase is essential for viability and plays a role in the pathogenesis of Yersinia pseudotuberculosis and Vibrio choleraeS M Julio
Department of Molecular, University of California, Santa Barbara, California 93106, USA
Infect Immun 69:7610-5. 2001..Dysregulation of Dam activity may provide a means for the development of vaccines against varied bacterial pathogens...
- Detection of antibodies to toxin-coregulated pili in sera from cholera patientsStephen R Attridge
Department of Molecular Biosciences, The University of Adelaide, Adelaide, South Australia, Australia
Infect Immun 72:1824-7. 2004..These MAbs were used in immunoblotting studies to assess seroconversion to El Tor TCP following cholera. Clear anti-pilus responses were observed in five of nine patients...
- Induction of protective immunity by synthetic Vibrio cholerae hexasaccharide derived from V. cholerae O1 Ogawa lipopolysaccharide bound to a protein carrierAnatoly Chernyak
Laboratory of Medicinal Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
J Infect Dis 185:950-62. 2002..Further studies are required to increase understanding of the reason for differential protection...
- Prevention of choleraNoel W Preston
Lancet 363:898. 2004
- Disaster, water, cholera, vaccines, and hopeJeffrey M Drazen
N Engl J Med 352:827. 2005
- Transcriptional responses of intestinal epithelial cells to infection with Vibrio choleraeNeil R Stokes
Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA
Infect Immun 72:4240-8. 2004Vibrio cholerae is a noninvasive enteric bacterium that causes the severe diarrheal disease cholera. Candidate cholera vaccines have been engineered by deleting genes encoding known virulence factors in V...
- Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinaseDuncan E S Stewart-Tull
Division of Infection and Immunity, Institute of Biomedical and Life Sciences, Joseph Black Building, University of Glasgow, Glasgow G12 8QQ, UK
Vaccine 22:2137-45. 2004..cholerae cells and hence reduce delivery of toxin to receptors. These mucinases, neuraminidase and proteinases, may be useful components of acellular, toxoided cholera vaccines for human immunisation.
- A Vibrio cholerae classical TcpA amino acid sequence induces protective antibody that binds an area hypothesized to be important for toxin-coregulated pilus structureRonald K Taylor
Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, New Hampshire 03756, USA
Infect Immun 72:6050-60. 2004..Whole-cell, killed, and live-attenuated oral cholera vaccines are in use...
- Current immunizations for travelBeth D Kirkpatrick
University of Vermont College of Medicine, MCHV Campus, 303 Burgess Building, 111 Colchester Avenue, Burlington, VT 05401, USA
Curr Opin Infect Dis 16:369-74. 2003..Some of these diseases are preventable, and vaccination remains a cornerstone of travel medicine. Vaccines that are important for international travel are reviewed, in a succinct update based on the most recent literature...
- Cholera caused by Vibrio cholerae O1 induces T-cell responses in the circulationTaufiqur Rahman Bhuiyan
Immunology Laboratory, Laboratory Sciences Division, International Centre for Diarrhoeal Disease Research, Dhaka 1000, Bangladesh
Infect Immun 77:1888-93. 2009..cholerae O1. Further studies are needed to determine if such responses are also stimulated after immunization with oral cholera vaccines and if these responses play a role in protection following exposure to cholera.
- Vibrio cholerae flagellins induce Toll-like receptor 5-mediated interleukin-8 production through mitogen-activated protein kinase and NF-kappaB activationLisa M Harrison
Department of Microbiology and Immunology, University of Maryland Baltimore School of Medicine, Baltimore, Maryland 21201, USA
Infect Immun 76:5524-34. 2008Vaccine reactogenicity has complicated the development of safe and effective live, oral cholera vaccines. Delta ctx Vibrio cholerae mutants have been shown to induce inflammatory diarrhea in volunteers and interleukin-8 (IL-8) production ..
- The development of an international reference panel of monoclonal antibodies for the differentiation of hog cholera virus from other pestivirusesS Edwards
Central Veterinary Laboratory, Ministry of Agriculture Fisheries and Food, New Haw, Weybridge, Surrey, UK
Vet Microbiol 29:101-8. 1991..Using the panel it was possible to identify specifically all strains and isolates of hog cholera virus, hog cholera vaccines derived from 'C' strains, and most strains of bovine viral diarrhoea/border disease (BVD/BD) viruses (..
- [Cholera]Jean Michel Fournier
Unité du Choléra et des Vibrions, Centre National de Référence des Vibrions et du Choléra, Institut Pasteur, Paris
Presse Med 36:727-39. 2007..To date, two oral cholera vaccines have been shown to offer good (more than 70%) short-term (one year) protection...
- Enteric infections and the vaccines to counter them: future directionsMyron M Levine
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Vaccine 24:3865-73. 2006..Because of the poor uptake of the new typhoid and cholera vaccines licensed since 1985, it will be important to create reliable, long-term demand for the next generation of ..
- Cloning of a gene (zot) encoding a new toxin produced by Vibrio choleraeB Baudry
Department of Medicine, University of Maryland School of Medicine, Baltimore
Infect Immun 60:428-34. 1992Live oral candidate cholera vaccines have previously been constructed by deletion of Vibrio cholerae sequences encoding the enzymatically active A subunit of the cholera toxin...
- Vibrio cholerae: lessons for mucosal vaccine designAnne L Bishop
Department of Molecular Biology and Microbiology, Tufts University School of Medicine and Howard Hughes Medical Institute, Boston, MA 02111, USA
Expert Rev Vaccines 10:79-94. 2011..will continue to confound our ability to eradicate cholera through improvements to infrastructure, and thus cholera vaccines are needed...
- Bacterial adhesion to mucosal surfacesR K Taylor
Department of Microbiology and Immunology, University of Tennessee, Memphis 38163, USA
J Chemother 3:190-5. 1991..Pilin or peptides corresponding to the epitopes recognized by the monoclonal antibodies represent possible immunogens for improved cholera vaccines.
- Lipopolysaccharides of Vibrio cholerae: III. Biological functionsS N Chatterjee
Saha Institute of Nuclear Physics, 1 AF Bidhannagar, Sector 1, Calcutta 700 064, India
Biochim Biophys Acta 1762:1-16. 2006..The need for the continuous serogroup surveillance and monitoring of the environmental waters and the role of LPS in the designing of newer cholera vaccines has been discussed briefly in conclusion.
- Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variationP Gilbert
Department of Biostatistics, Harvard School of Public Health, 655 Huntington Ave, Boston, MA 02115, USA
J Clin Epidemiol 54:68-85. 2001..These analyses reveal intriguing trends for Genentech's monovalent rgp120 HIV-1 vaccine, for two whole-killed-cell oral cholera vaccines, and for other vaccines.
- Antisera to selected outer membrane proteins of Vibrio cholerae protect against challenge with homologous and heterologous strains of V. choleraeM Das
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston 77555 1070, USA
FEMS Immunol Med Microbiol 22:303-8. 1998..cholerae Ogawa and O139 strains. These results have significance in the development of vaccines to V. cholerae, as the hyperexpression of these OMP encoding genes in vaccine strains may improve the efficacy of cholera vaccines.
- Identification of a vibrio cholerae RTX toxin gene cluster that is tightly linked to the cholera toxin prophageW Lin
Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 96:1071-6. 1999..Furthermore, the RTX toxin of V. cholerae may be associated with residual adverse properties displayed by certain live, attenuated cholera vaccines.
- GENETIC ANALYSIS OF CHOLERA TOXIN STRUCTURE AND FUNCTIONRandall K Holmes; Fiscal Year: 2010..No vaccine against cholera or ETEC diarrhea is approved in the United States, and cholera vaccines used elsewhere have significant limitations...
- GENETIC ANALYSIS OF CHOLERA TOXIN STRUCTURE AND FUNCTIONRandall Holmes; Fiscal Year: 2007..No vaccine against cholera or ETEC diarrhea is approved in the United States, and cholera vaccines used elsewhere have significant limitations...
- Epidemiology and Ecology of Vibrio cholerae in BangladeshRichard Bradley Sack; Fiscal Year: 2010..The very recent availability of inexpensive oral cholera vaccines makes this objective even more relevant...
- Study of transmissible forms of Vibrio choleraeAndrew Camilli; Fiscal Year: 2007..of transmission of this and perhaps other water-borne pathogens, it will aid in the development of new cholera vaccines that target the antigens of 'incoming' vibrios, and it may suggest new approaches for the prevention of the ..
- STUDY OF VIBRIO INTESTINAL PHYSIOLOGY AND PATHOGENICITYAndrew Camilli; Fiscal Year: 2004..of virulence gene expression during infection of an intact host, but will aid in the development of new cholera vaccines and suggest new approaches for the prevention of the dissemination of this lethal organism.
- SIGMA54 AND VIBRIO CHOLERAE PATHOGENESISKARL KLOSE; Fiscal Year: 2003..54 and FlrC-dependent colonization genes and promoters may be useful in the development of live attenuated cholera vaccines, and manipulation of virulence factor repression could have practical applications for anti-cholera therapy.
- GENTICS DETERMINATION OF VIRULENCE OF VIBRIO CHOLERAERonald Taylor; Fiscal Year: 1993..intelligently incorporate the participating molecules and any antigenic variants into the design of improved cholera vaccines. Most of this proposal involves a genetic analysis of TCP (toxin regulated pilus) mediated colonization...
- DEVELOPMENT OF A LIVE ORAL CHOLERA VACCINEJames B Kaper; Fiscal Year: 2010..We have also generated new insights into intestinal inflammation caused by these reactogenic cholera vaccines by using gene arrays of epithelial cell transcriptional responses...
- DEVELOPMENT OF A LIVE ORAL CHOLERA VACCINEJAMES KAPER; Fiscal Year: 2007..We have also generated new insights into intestinal inflammation caused by these reactogenic cholera vaccines by using gene arrays of epithelial cell transcriptional responses...
- Causal inference in infectious disease prevention studiesMichael G Hudgens; Fiscal Year: 2010..A motivating data set is from a trial of cholera vaccines in Bangladesh...
- Causal inference in infectious disease prevention studiesMichael G Hudgens; Fiscal Year: 2011..A motivating data set is from a trial of cholera vaccines in Bangladesh...
- DEVELOPMENT OF A LIVE ORAL CHOLERA VACCINEJAMES KAPER; Fiscal Year: 2005..The development of attenuated cholera vaccines has been plagued by the fact that V...
- GENETIC ANALYSIS OF TOXINOGENESIS IN VIBRIO CHOLERAEJohn Mekalanos; Fiscal Year: 2007..Finally, derivatives of 0395-N1 which are suitable for use as a dead, oral cholera vaccines will be constructed which hyperproduce the B subunit of the toxin in both a secreted and nonsecreted form.
- Cholera Pathogenesis, mucinase activity and motilityJorge Benitez; Fiscal Year: 2007..cholerae main virulence factors: cholera toxin and toxin co-regulated in the infant mouse intestine. This knowledge will facilitate the development of improved cholera vaccines.
- Mucosal immune response to oral cholera vaccine Peru 15Firdausi Qadri; Fiscal Year: 2007..cholerae. ..
- Global TravEpiNet: Global Travelers' Health National Research Center ConsortiumEdward Ryan; Fiscal Year: 2007..We would use data generated through this network in an attempt to estimate national vaccine coverage rates (and other preventative strategies) among international travelers. ..
- Mucosal Immunity to Antigens Expressed by V.choleraeEdward Ryan; Fiscal Year: 2006..difficile toxin A is injected into ligated ileal loops of vaccinated and control animals. ..
- High throughput proteomic analysis of Salmonella entericaEdward Ryan; Fiscal Year: 2007....
- Transcutaneous and oral-transcutaneous cholera immunization with TcpA and Peru15Edward Ryan; Fiscal Year: 2007..Protective immunity to V. cholerae is poorly understood, and development of highly effective cholera vaccines has been problematic...
- Application of IVIAT to Bacillus anthracisEdward Ryan; Fiscal Year: 2004..IVIAT is an established protocol in our laboratory, and this preliminary collaborative study should lay a foundation for subsequent analysis of identified B. anthracis genes and their products. ..